HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks Education
Visit Zacks'
Education section for investing guides and other free resources to make you a better investor.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


MASI: Masimo Corp - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

MASIMO CORP (NASD)
MASI 26.75 0.13 (0.49%) Vol.  156,902 16:00 ET

Day Low - High 26.47 - 27.08
52wk Low - High 21.00 - 31.43
Avg Volume 402,521
Industry MED INSTRUMENTS
Market Cap 1.54 B
Div - Yield 0.00 - 0.00
PE (forward) 25.37
PEG Ratio 1.31
Current Year Est. 1.05
EPS Last Year 0.90
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


downgraded 01/12/2010
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 11/18/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
MASIMO CORP MASI PREMIUM
CANTEL MED CORP CMN PREMIUM
SONOSITE INC SONO PREMIUM
RINO INTL CORP RINO PREMIUM
See all MED INSTRUMENTS Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.75
ABR (Last Week) 1.75
# of Recs in ABR 14
Average Target Price 32.20
Industry Rank by ABR 62 out of 217
Rank in Industry 25 out of 45
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate MASI?
Buy
Sell
Find out what the Zacks Community
thinks of MASI at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR MASI
Zacks Blog: Positive Results for Masimo
Jan 25, 2010
Zacks Blog: New CPT Code for Masimo
Jan 04, 2010
Zacks Blog: FDA Clears ZOLL Product
Dec 31, 2009
Zacks Blog: Masimo in Expansion Mode
Dec 29, 2009
Zacks Blog: Masimo’s New Customer
Dec 14, 2009
Zacks Blog: Masimo’s New Product
Dec 02, 2009
Zacks Blog: Advocate Renews Deal with Masimo
Nov 27, 2009
Zacks Equity Research: Report for MASI
Nov 18, 2009
More Zacks Commentary
NEWS
Masimo to Report Fourth Quarter and Full Year 2009 Financial Results After Market Close on February 16, 2010
Feb 02, 2010
St. Luke's Episcopal Hospital Becomes First in Texas to Monitor Post-surgical Patients With Masimo Patient SafetyNet(TM)
Jan 26, 2010
Landmark Study Shows Masimo SET(R) Pulse Oximetry and Patient SafetyNet(TM) Can Help Hospitals Dramatically Decrease Rescue Events and ICU Transfers, and ICU Days
Jan 22, 2010
BMEYE Receives CE Mark to Launch First Noninvasive Cardiovascular Monitor with Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Technology in Europe
Jan 21, 2010
BMEYE Receives CE Mark to Launch First Noninvasive Cardiovascular Monitor with Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Technology in Europe
Jan 21, 2010
U.S. Department of Homeland Security Issues Federal Warning About Duty-related Carbon Monoxide (CO) Dangers for Firefighters
Jan 19, 2010
New Published Study Finds Masimo PVI(R) Predicts Fluid Responsiveness as Accurately as Invasive Stroke Volume Variation in Mechanically-Ventilated Patients
Jan 14, 2010
SEDLine(TM) Announces Acquisition of Hospira Brain Function Monitoring Business
Jan 12, 2010
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate 0.22 0.24 0.88 1.05
Number of Estimates 12 11 14 13
Low Estimates 0.21 0.23 0.87 0.98
High Estimate 0.23 0.28 0.89 1.10
Year Ago EPS 0.24 0.22 0.77 0.88
EPS Growth -8.68% 10.33% 13.91% 19.62%

More Estimates

COMPANY DESCRIPTION
Masimo develops innovative monitoring technologies that significantly improve patient care -- helping solve unsolvable problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry's ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.

Full Company Report
FINANCIALS
EPS TTM .9
Sales 307.07
Net Income 38.64
Price/Earnings 29.58
Price/Book 5.67
Price/Cash Flow 29.81
Price/Sales 4.52


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research